EUVIMEDEUVIMED entdecken
Fallbericht

First report on a case series of Patulous Eustachian tube following GLP-1 receptor agonist-induced weight loss

Holger Sudhoff

European Archives of Oto-Rhino-Laryngology · 2025

DOI: 10.1007/s00405-025-09604-5 ↗

Kurz gefasst

Fallbericht in der Zeitschrift European Archives of Oto-Rhino-Laryngology, 2025. Verfasst von Holger Sudhoff. Beteiligte Einrichtung: Department of Otorhinolaryngology, Head and Neck Surgery, Kopfzentrum Bielefeld, Am Stadtholz 39, 33609, Bielefeld, Germany. holger.sudhoff@kopfzentr…. Hauptthemen laut MEDLINE: Eustachian Tube, Weight Loss, Glucagon-Like Peptide-1 Receptor Agonists, Ear Diseases. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: To describe seven cases of patulous Eustachian tube (PET, "Tuba aperta") arising in adult patients undergoing significant weight loss with GLP-1 receptor agonists (semaglutide [Ozempic®] or tirzepatide [Mounjaro®]). METHODS: Retrospective descriptive case series of patients presenting to our otolaryngology clinic between June 2024 and June 2025 with symptoms of autophony, aural fullness, and audible breathing. All had initiated GLP-1 agonist therapy ≥ 3 months prior and achieved ≥ 8% body-weight reduction. Diagnosis of PET was confirmed by patient symptoms, otoscopy, digital volume tomography, reflex decay tympanometry and tubomanometry. RESULTS: Seven patients (5 female, 2 male; age 28-56 years) developed bilateral (n = 5) or unilateral (n = 2) PET after 4-10 months of GLP-1 therapy. Weight loss ranged from 8.2 to 18.7% of baseline. Common symptoms were autophony (7/7), intermittent aural fullness (6/7), and hearing one's own breathing (5/7). Conservative management led to symptom improvement in one patient; six required injections of VOX-Implants® into the affected Eustachian tubes with resolution of symptoms. CONCLUSION: Significant weight loss from GLP-1 receptor agonists may predispose susceptible individuals to PET. Clinicians should be aware of this potential otologic side effect and consider early conservative measures.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Eustachian TubeWeight LossGlucagon-Like Peptide-1 Receptor AgonistsEar DiseasesHypoglycemic AgentsHumansAdultFemaleMaleMiddle AgedRetrospective Studies

Stichwörter der Autor:innen

AutophonyEustachian tube dysfunctionGLP-1 receptor agonistPatulous eustachian tubeRapid weight lossSemaglutide (Ozempic®)Tirzepatide (Mounjaro®)Tuba aperta

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsHypoglycemic Agents

Autor:innen und Institutionen

  • Department of Otorhinolaryngology, Head and Neck Surgery, Kopfzentrum Bielefeld, Am Stadtholz 39, 33609, Bielefeld, Germany. holger.sudhoff@kopfzentrum-bielefeld.de.
  • University of Barcelona Medical School, Villaroel 170, Esc,.8, 2 A, Barcelona, 08036, Spain. holger.sudhoff@kopfzentrum-bielefeld.de.
  • Bielefeld ENT Institute (BENTI), Bielefeld, Germany. holger.sudhoff@kopfzentrum-bielefeld.de.

Zitieren

APA

Sudhoff, H. (2025). First report on a case series of Patulous Eustachian tube following GLP-1 receptor agonist-induced weight loss. European Archives of Oto-Rhino-Laryngology. https://doi.org/10.1007/s00405-025-09604-5

Vancouver

Sudhoff H. First report on a case series of Patulous Eustachian tube following GLP-1 receptor agonist-induced weight loss. European Archives of Oto-Rhino-Laryngology. 2025. doi:10.1007/s00405-025-09604-5

BibTeX
@article{Sudhoff2025,
  author = {Sudhoff, Holger},
  title = {First report on a case series of Patulous Eustachian tube following GLP-1 receptor agonist-induced weight loss},
  journal = {European Archives of Oto-Rhino-Laryngology},
  year = {2025},
  doi = {10.1007/s00405-025-09604-5}
}
Kostenlos starten →